AUTHOR GUIDELINES

Aims & scope
The Journal of the European Academy of Dermatology and Venereology (JEADV) is the official publication of the European Academy of Dermatology and Venereology (EADV). The JEADV is one of the leading international journals in the field of Dermatology and Venereology. Our target audience is clinician dermatologists in hospitals or in private practice, as well as researchers and everybody interested in the skin.

The aim of the JEADV is to deliver the highest level of dermatological knowledge to its readership, publishing clinical and translational research articles, clinical trial reports, and systematic and state of the art reviews. The Journal publishes original articles, review articles, short reports and also welcomes submissions of Letters to the Editor expressing opinions on current and/or controversial issues as well as observations of general importance. With thought-provoking features like editorials, commentaries and the Historical Perspectives series, the Journal strives to be an engaging and relevant platform for dermatologists and venereologists in Europe and beyond.

Furthermore, the JEADV is the place where the European Clinical Guidelines derived from cooperation between the European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the Union Européenne des Médecins Spécialistes (UEMS) and other relevant subspecialty societies are published.

Manuscript categories
JEADV invites the following types of submissions:

Original Articles
Original articles are the Journal’s primary mode of communication. Original articles must include a structured abstract (maximum 300 words) and should not exceed 3000 words of body text (i.e. excluding the abstract and reference list). The addition of tables and figures (with figure legends) is encouraged.

Manuscripts reporting randomized controlled trials (RCTs) must follow the CONSORT statement. RCTs will not be considered by JEADV without submission of a completed CONSORT checklist.

Review Articles
The Journal is particularly keen to publish concise, high-quality review articles of recent advances in laboratory or clinical research. Review articles may be solicited by the Editor-in-Chief or may be submitted by authors for publication subject to peer review. Review articles must include an unstructured abstract (maximum 300 words) and should not exceed 5000 words of body text. Use of tables and figures (with figure legends) is encouraged.

Short Reports
Brief data papers on very new findings are published as short reports. Short reports must include a structured abstract and should not exceed 1500 words of body text, 4 figures/tables and 20 references.

Letters to the Editor
Letters to the Editor (Correspondence) may be in response to issues arising from recently published articles, or short, free-standing pieces expressing an opinion. Case reports will be considered and published as Letters to the Editor if they represent an outstanding contribution to the treatment of a specific skin disorder or provide new clinical information. Letters to the Editor should not have an abstract or acknowledgements, should be formatted in one continuous section (no subheadings) and should not exceed 600 words, 10 references and a total of 2 figures. No supplementary material (figure, table or text) is allowed when submitting a Letter to the Editor. All letters are published online-only, although they are each published as a part of a specific issue.

Book Reviews
The Journal publishes reviews of recent books in dermatology and venereology and in related fields. Book reviews are solicited by the Editor-in-Chief. Proposals with adequate information on the book may also be submitted by prospective book reviewers. All book reviews are subject to expert review.

Submission of manuscripts
All submissions should be made online at the JEADV ScholarOne Manuscripts site (formerly known as Manuscript Central) —http://mc.manuscriptcentral.com/jeadv

New users should first create an account. Once a user is logged onto the site, submissions should be made via the Author Centre. Authors must also supply: (i) completed Conflicts of Interest Disclosure form(s)—Each listed author must complete the form electronically. It is the responsibility of the corresponding author to upload – on behalf of all co-authors – completed COI forms as ‘Supplementary Material for Review’ via ScholarOne Manuscripts (formerly known as Manuscript Central) at the same time as the manuscript submission. Manuscripts will not be sent for peer review without these forms. (See Declarations for further information.)
**Contacting the editorial office**
Asao Sarukawa, Head of Editorial and Publication – JEADV  
EADV Headquarters, Via S. Balestra 22 B, 6900 Lugano, Switzerland.  
Tel: +41 91 973 45 20; Email: jeadv@eadv.org

**Preparation of manuscripts**
Manuscripts must be submitted in grammatically correct English (American or British usage is accepted, but not a mixture of the two). Manuscripts that do not meet this standard cannot be reviewed. Authors for whom English is a second language may wish to consider having their manuscript professionally edited before submission to improve the English. A list of independent suppliers of editing services can be found at http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.

The main text of each manuscript should be supplied in a format compatible with Word (.doc or .docx). Do not submit text saved in PDF format (.pdf). Tables and flow charts are considered textual and should also be supplied in a format professionally compatible with Word. Tables and flow charts submitted in TIFF, JPG, PDF or PowerPoint files are NOT acceptable. Figures must be uploaded as separate figure files in appropriate formats (see section Formats). All manuscripts must be typed in 12 pt font with margins of at least 2.5 cm. Submissions must comply with the word limits defined in Manuscript Categories and, where appropriate, please include:

**Title page**
A title page must be provided for all submissions regardless of the type of manuscript being submitted. Please note that without title page, the submission will not be sent to peer review and will be instantly returned to the authors so they can update their submission. The first page of all manuscripts should contain the following information:

1. the title of the paper  
2. a list of key words (2–6 article key words)  
3. manuscript word, table and figure count  
4. names of authors as initial(s) followed by surnames  
5. names of the institutions at which the research was conducted, clearly linked to respective authors  
6. name, address, telephone and fax number and email address of corresponding author  
7. a statement of all funding sources that supported the work  
8. any conflict of interest disclosures (see sections Declarations and Submission of Manuscripts).

**Abstracts**
Authors submitting original articles or short reports should note that structured abstracts are required. The structured abstract should adopt the format as follows: Background, Objectives, Methods, Results and Conclusions.

Review articles require abstracts but they should not be structured, namely, they should not have subheadings. Letters to the Editor do not require abstracts. Abstracts should contain no citations to previously published work.

**Text**
The main text of a manuscript should in general, but not necessarily, be divided into sections with the headings: Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Legends and Figures. Letters to the Editor should NOT include Acknowledgements.

**Tables and figures**
Tables and figures should not be inserted in the appropriate place in the text but should be provided as separate files and should be uploaded below the main text.

Tables and figures should be referred to in text as follows: Fig. 1, Figs 2–4; Table 1, Table 2. The place at which a table or figure is to be inserted in the printed text should be indicated clearly in the manuscript. A title should be provided for each table. Where a figure has more than one panel, each panel should be labelled in the top left-hand corner using lower case letters in parentheses, that is, (a), (b), etc., and a brief description of each panel given in the figure legend.

Colour illustrations are welcomed and all colour is published free of charge to the author.

Authors are themselves responsible for obtaining permission to reproduce previously published materials (e.g. figures, diagrams, charts, tables.), for which they do not own the copyright. Permissions must be obtained from the original publisher or copyright holder and the evidence must be provided to the Editorial Office. You must acknowledge the original source in the figure/table legends, as requested by the original publisher. When an individual is identifiable in a photograph written permission must be obtained (see Declarations).

**Figure legends**
Each figure must have a legend that explains its purpose without reference to the text. Figure legends should be listed in numerical order, at the end of the text document, separate from the figure files.

**Formats**
Clinical photographs may be supplied in GIF, JPEG, PNG or TIFF format at the time of submission, but only TIFF files (and exceptionally JPEG files, as original format) are suitable for production and printing. JEADV has a dedicated medical illustrator who works on accepted manuscripts to format/redesign the tables/figures to comply with the Journal’s style. If a manuscript is accepted, the corresponding author will be contacted to
provide high-quality photographs at their actual size, which is 100% of their print dimension in TIFF format, at a minimum resolution of 300 pixels per inch and in RGB colour mode.

Vector graphics (e.g. graphs, diagrams, histograms) should be provided in editable PPT, PDF, EPS or AI files, either in greyscales or RGB at the appropriate resolutions: 300 dpi for colour figures; 600 for black and white figures; 1200 dpi for line-art figure.

Flow charts should be provided in an editable Word format.

Images and photographs destined to redesign should not contain any added lettering (a,b,c,...), arrows or symbols.

If submitting artwork electronically, please read the information at: http://authorservices.wiley.com/bauthor/illustration.asp

References
References should be in Vancouver format and appear as consecutive, unbracketed superscript numbers in the text, for example, ‘in our previous reports’ and those of Smith et al. and should be listed numerically in the reference list at the end of the article.

Format references as below, using standard (MEDLINE) abbreviations for journal titles. If more than six authors, include the first three authors followed by et al. If six or fewer authors, please include all authors’ names.

1 de Berker DAR, Baran R, Dawber RPR. The nail in dermatological diseases. In Baran R, Dawber RPR, de Berker DAR, Hanke E, Tosti A, eds, Baran and Dawber’s Diseases of the Nails and their Management, 3rd edn. Blackwell Science Ltd, Oxford, 2001: 172–192.
2 Wollina U, Hansel G. The use of topical calcineurin inhibitors in lupus erythematosus: an overview. J Eur Acad Dermatol Venereol 2008; 22: 1–6.
3 Graham-Brown R, Burns T. Lecture Notes: Dermatology. Wiley-Blackwell, Oxford, 2006.
4 British Lymphology Society. Consensus document on the management of cellulitis in lymphoedema. 2007. URL http://www.lymphoedema.org/lsn/consensus_on_cellulitis_dec_06.pdf (last accessed: 28 November 2007).

Supplementary data
Supplementary material, including appendices, datasets, video files, may be uploaded at the submission stage and is considered for inclusion in the online version of article during the review process. The supplementary material will not be edited for style. No supplementary material is allowed with the submission of a Letter to the Editor.

Revised manuscripts
Authors should take the time required to make all necessary revisions before submitting their revised manuscript. Please upload a letter from the authors together with the main text responding to each of the reviewers’ comments point by point, clearly referring to the text by section, paragraph and sentence when necessary. Indicate changes in your manuscript with underlining or other forms of highlighting, for example, colour. Whatever method is used, it is important that the changes are clear to both editors and reviewers.

Reporting standards
Manuscripts reporting randomized controlled trials (RCTs) must follow the CONSORT statement. RCTs will not be considered by JEADV without submission of a completed CONSORT checklist. Checklists should be uploaded during manuscript submission using file designation ‘Supplementary files for review’.

JEADV data sharing policy
JEADV encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors may provide a data availability statement, including a link to the repository they have used, in order that this statement can be published in their paper. Shared data should be cited.

Declarations

Original publication
Submission of a manuscript will be held to imply that it contains original unpublished work and is not being submitted for publication elsewhere at the same time. The author must supply a full statement to the Editor about all submissions and previous reports that might be regarded as redundant or duplicate publication of the same or very similar work.

Conflicts of interest
Authors are responsible for disclosing all financial and personal relationships between themselves and others that might be perceived by others as biasing their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. (See Submission of Manuscripts.)

Ethics
When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients’ names, initials or hospital numbers, especially in illustrative material. When reporting experiments on animals, indicate whether the institution’s or a national research council’s guide for, or any national law on, the care and use of laboratory animals was followed. A statement describing explicitly the ethical background to the studies being reported should be included in all manuscripts in the Materials and Methods section. Ethics committee or institutional review board approval should be stated.
Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be published in written descriptions, photographs and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Identifying details should be omitted if they are not essential but patient data should never be altered or falsified in an attempt to attain anonymity. Complete anonymity is difficult to achieve and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity.

Authorship
All persons designated as authors should qualify for authorship and all those who qualify should be listed. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One or more authors should take responsibility for the integrity of the work as a whole, from inception to published article. Authorship credit should be based only on (i) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; (ii) drafting the article or revising it critically for important intellectual content; (iii) final approval of the version to be published. Conditions (i), (ii) and (iii) must all be met. Acquisition of funding, the collection of data or general supervision of the research group, by themselves, do not justify authorship. All others who contributed to the work who are not authors should be named in the Acknowledgements section.

Committee on Publication Ethics (COPE)
As a member of the Committee on Publication Ethics (COPE), adherence to these submission criteria is considered essential for publication in the JEADV; mandatory fields are included in the online submission process to ensure this. If, at a later stage in the submission process or even after publication, a manuscript or authors are found to have disregarded these criteria, it is the duty of the Editor to report this to COPE. COPE may recommend that action be taken, including but not exclusive to, informing the authors' professional regulatory body and/or institution of such a dereliction. The website for COPE may be accessed at: http://www.publicationethics.org.uk

Additional information on acceptance

Copyright
If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the licence agreement on behalf of all authors on the paper.

For authors signing the copyright transfer agreement
If the OnlineOpen option is not selected, the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

For authors choosing OnlineOpen
If the OnlineOpen option is selected, the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):
- Creative Commons Attribution Non-Commercial License OAA
- Creative Commons Attribution Non-Commercial-NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright–License.html.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK), you will be given the opportunity to publish your article under a CC-BY licence supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this licence:
- Creative Commons Attribution License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright–License.html.

Proofs
Page proofs will be sent to the corresponding author and should be returned within 3 days of receipt to the Production Editor. Significant textual alterations are unacceptable at proof stage without the written approval of the Editor, and they are likely to result in the delay of publication.

The corresponding author will receive an email alert containing a link to a secure web site. A working email address must therefore be provided for the corresponding author. In the absence of the corresponding author, please arrange for a colleague to access the email to retrieve the proofs.

Please note that you have full responsibility for what is stated in the proofs of your manuscript. However, the proofs are
checked thoroughly by the *JEADV* editorial team, and if we do not receive corrections after several automated reminders to the email address supplied for the corresponding author, then we will assume that we have your approval for publication.

**Author services**

Author Services enables authors to track their article – once it has been accepted – through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production. The author will receive an email with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete email address is provided when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

**Early view**

*JEADV* is covered by the Publisher’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found online at http://www.doi.org/faq.html.

**Offprints**

Free access to the final PDF offprint of your article will be available via author services only. Please therefore sign up for author services if you would like to access your article PDF offprint and enjoy the many other benefits the service offers. Additional offprints can be ordered on the offprint order form, which accompanies the proofs.

**Disclaimer**

The Publisher, the European Academy of Dermatology and Venereology (EADV) and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, the EADV and Editors or the products advertised.